+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07399665

Real-World Observational Study of Tezepelumab Use and Outcomes in Adults with Chronic Rhinosinusitis With Nasal Polyps in Russia

Led by AstraZeneca · Updated on 2026-09-16

110

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing adults with Chronic Rhinosinusitis With Nasal Polyps CRSwNP, with or without asthma, who have recently started treatment with tezepelumab. This observational study collects data from real-world clinical settings in Russia to understand how tezepelumab is used and its effects outside of controlled trials. The study includes about 110 adults treated according to their doctors prescriptions. Participants have initiated tezepelumab treatment no more than 4 weeks before joining the study. This non-interventional study gathers information from medical records and primary data over a year, focusing on changes in nasal polyp status and nasal congestion. The study is conducted at approximately 10 sites, following patients for up to 52 weeks after starting tezepelumab. During the study, participants medical records will be reviewed, and assessments including nasal endoscopy, nasal blockage scoring, and symptom questionnaires like SNOT-22 will be collected at baseline and at weeks 4, 24, and 52. Researchers will also evaluate healthcare use related to CRSwNP and asthma and monitor treatment duration and discontinuation. The study aims to provide comprehensive real-world data on tezepelumabs use and patient outcomes over one year.

CONDITIONS

Brief Title

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here